RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

512 Episodes

  1. Lessons from Pitching Venture Capitalists

    Published: 11/15/2017
  2. Health Canada Scraps Plans for Orphan Drug Framework

    Published: 11/8/2017
  3. New Investment Boosts Rare Disease Drug Accelerator

    Published: 11/1/2017
  4. Understanding Rare Disease Caregiver Needs

    Published: 10/25/2017
  5. Deriving Rare Disease Therapies from Human Plasma

    Published: 10/18/2017
  6. Learning to Live with Purpose

    Published: 10/11/2017
  7. A Mother's Race to Find a Treatment for Her Daughter's Ultra-Rare Condition

    Published: 10/4/2017
  8. Screening for Rare Diseases

    Published: 9/27/2017
  9. A Look at the Changing World of Work for People with a Chronic Illness

    Published: 9/20/2017
  10. Aligning Interests in Rare Disease Partnerships

    Published: 9/13/2017
  11. A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development

    Published: 9/6/2017
  12. A Patient Group Crafts Guidelines for Working with Pharma

    Published: 8/30/2017
  13. Bringing Innovation to Business Models for Rare Disease Drug Development

    Published: 8/23/2017
  14. Rethinking Accessibility and Dependency

    Published: 8/16/2017
  15. How Simon Wheatcroft, Blinded by a Rare Disease, Became an Ultramarathoner

    Published: 8/9/2017
  16. Spark Hoping Its Luxturna Will Become First FDA-Approved Gene Therapy

    Published: 8/2/2017
  17. What Rare Patient-Investors Can Learn From Venture Capitalists

    Published: 7/26/2017
  18. Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants

    Published: 7/19/2017
  19. Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early

    Published: 7/12/2017
  20. Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

    Published: 7/5/2017

19 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.